Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01055912 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure
A Phase 2 study, sponsored by CardioKine.
- Completed
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
NCT01055912 is a Phase 2 study that has completed, run by CardioKine. The registered enrollment target is 170 participants.
The verdict
NCT01055912, a Phase 2 study, has completed, sponsored by CardioKine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of oral lixivaptan capsules in patients with congestive heart failure.
Interventions
- DRUG Placebo
- DRUG Lixivaptan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01055912
The ClinicalTrials.gov registry entry for NCT01055912 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CardioKine, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01055912 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01055912 about?
NCT01055912 is a clinical study titled "Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure". The purpose of this study is to evaluate the effects of oral lixivaptan capsules in patients with congestive heart failure.
What is the current status of trial NCT01055912?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2010-01.
What interventions are being tested in trial NCT01055912?
The interventions under investigation include: Placebo (DRUG), Lixivaptan (DRUG).
Who is sponsoring clinical trial NCT01055912?
This trial is sponsored by CardioKine, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.